RecruitingNot Applicable

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

South Korea70 participantsStarted 2025-04-02

Plain-language summary

This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.

Who can participate

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
✓. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4
✓. Subjects who have never used TNFi, JAKi, or IL-17i drugs before
✓. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
✓. Subjects who have a time of less than 5 years since AS diagnosis
✓. Subjects who are above the age of 18 years and below 40years old
✓. Subjects who give informed consent form to participate in the study

Exclusion criteria

✕. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
✕. Subjects who have congenital/traumatic spinal deformities
✕. Subjects currently enrolled in other clinical studies
✕. Subjects who have any contraindications to secukinumab treatment

What they're measuring

Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

Timeframe: Baseline and 28 weeks

Trial details

NCT IDNCT06905288

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Novartis Pharmaceuticals, MD

+41613241111 thomas.paul@novartis.com

View on ClinicalTrials.gov More Ankylosing Spondylitis trials